Acta Ophthalmol:慢性中心性浆液脉络膜视网膜病变患者的眼底自发荧光模式演变

2018-04-25 cuiguizhong MedSci原创

英国伦敦UCL眼科研究所生物医学研究中心的Zola M近日在Acta Ophthalmol发表了一篇文章,他们确定了随着时间变化的慢性中心浆液性脉络膜视网膜病变(CSCR)中眼底自发荧光(FAF)的变化模式。

英国伦敦UCL眼科研究所生物医学研究中心的Zola M近日在Acta Ophthalmol发表了一篇文章,他们确定了随着时间变化的慢性中心浆液性脉络膜视网膜病变(CSCR)中眼底自发荧光(FAF)的变化模式。

他们回顾性的研究了112例慢性CSCR患者的157只眼睛,使用海德堡视网膜血管造影488 nm激发光和500 nm截止屏障过滤器来记录随着时间变化的FAF模式。

他们研究的平均随访时间为37.2个月。最常见的起始模式是粒状低自发荧光(51.0%)。慢性CSCR最早的变化是弥漫的超急性荧光,并且首次检测的4个月后发生。在这个阶段观察到的最常见的变化是,超反射点在超反射荧光区域内出现或消失。FAF模式从超自发荧光到低自发荧光的区域变化缓慢。只有25%的眼睛在36个月内表现出这样的变化。颗粒状低自发荧光模式平均需要24个月才能形成融合的低自发性荧光。

因此,他们认为,慢性中心浆液性脉络膜视网膜病变(CSCR)中的眼底自发荧光(FAF)随时间变化逐渐演变,因此不适用于临床试验。

原文出处:

Zola, M., et al., Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy. Acta Ophthalmol, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-12-01 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-12-23 oliver181
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
    2018-04-27 zutt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1849594, encodeId=6566184959484, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Dec 01 14:23:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707778, encodeId=6a931e0777852, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Tue Feb 05 10:23:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687015, encodeId=f322168e015cd, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Sun Feb 10 14:23:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745850, encodeId=b1581e4585044, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Sun Dec 23 23:23:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270046, encodeId=d71912e004605, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413941, encodeId=b5d7141394184, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541338, encodeId=934f1541338a0, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Fri Apr 27 13:23:00 CST 2018, time=2018-04-27, status=1, ipAttribution=)]